NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal.

Journal:

Journal of Clinical Oncology

Published:

2026-01-08

DOI:

10.1200/jco-25-00929

Affiliations:

14

Authors:

20

Go to article

Institutions	Authors	Share
The University of Texas MD Anderson Cancer Center, United States of America (USA)	5.000000	0.25
Vanderbilt University Medical Center (VUMC), United States of America (USA)	3.000000	0.15
The Ohio State University (OSU), United States of America (USA)	1.000000	0.05
The University of Texas Southwestern Medical Center (UT Southwestern Medical Center), United States of America (USA)	1.000000	0.05
Washington University in St. Louis (WUSTL), United States of America (USA)	1.000000	0.05
University of Colorado Anschutz Medical Campus (CU Anschutz), United States of America (USA)	1.000000	0.05
Northwestern University (NU), United States of America (USA)	1.000000	0.05
Rutgers University-Newark Campus, United States of America (USA)	1.000000	0.05
Barbara Ann Karmanos Cancer Institute, Wayne State University, United States of America (USA)	1.000000	0.05
Baptist Hospital, United States of America (USA)	1.000000	0.05
Georgetown University, United States of America (USA)	1.000000	0.05
University of Southern California (USC), United States of America (USA)	1.000000	0.05
The University of Chicago (UChicago), United States of America (USA)	1.000000	0.05
University of Michigan (U-M), United States of America (USA)	1.000000	0.05

Interested in Oncology and Carcinogenesis?